- Illustrating how AI is already changing the small molecule side of the pharmaceutical industry in both drug discovery and R&D
- Extrapolating from these examples to suggest biopharmaceutical manufacturing applications
- Drawing parallels from the industrialization of biologics manufacturing. How far away are we, and what should we as an industry be doing now to get ready?
- Discussing what small pilot programs and early test cases might look like, and the timelines involved in moving from proof of concept to industry-wide applications
Chief Operating Officer
Tina M. Larson is Chief Operating Officer at Recursion Pharmaceuticals. Recursion is re-imagining drug discovery using automation and artificial intelligence. Before joining Recursion she was Senior Vice President of Technical Operations at Achaogen, where she built Achaogen’s Technical Operations organization in support of late stage development and commercial launch of the company’s first product. Prior to Achaogen, she spent 20 years at Genentech and Roche, holding leadership positions in Technical Development, Manufacturing and Engineering. Ms. Larson worked on every commercial biopharmaceutical product launched from Genentech, and many clinical programs as well. In 2012, she was selected by the Genentech Executive Committee to be nationally recognized as their Healthcare Businesswomen’s Association Rising Star. Ms. Larson has a Bachelor of Science in Chemical Engineering from Colorado State University and currently serves on the Dean’s Advisory Board for the Walter Scott, Jr. College of Engineering.